Medpace Holdings, Inc. $MEDP Shares Sold by CX Institutional

CX Institutional trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 31.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,962 shares of the company’s stock after selling 1,390 shares during the quarter. CX Institutional’s holdings in Medpace were worth $1,569,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. NewEdge Advisors LLC boosted its holdings in Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Medpace during the 2nd quarter valued at approximately $296,000. Finally, M&T Bank Corp grew its position in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MEDP shares. Truist Financial upped their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Finally, TD Cowen lifted their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $584.18.

Medpace Stock Up 2.2%

Shares of NASDAQ:MEDP opened at $587.75 on Thursday. The company has a market cap of $16.40 billion, a PE ratio of 34.45, a P/E/G ratio of 2.57 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a 50-day simple moving average of $516.53 and a 200 day simple moving average of $492.28.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 earnings per share. Medpace’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 3,510 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total value of $2,106,035.10. Following the transaction, the chief executive officer owned 638,946 shares of the company’s stock, valued at $383,373,989.46. This represents a 0.55% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 31,087 shares of company stock valued at $16,203,054. Insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.